Tianjin Lisheng Pharmaceutical Co Ltd (002393) - Total Liabilities
Based on the latest financial reports, Tianjin Lisheng Pharmaceutical Co Ltd (002393) has total liabilities worth CN¥893.57 Million CNY (≈ $130.76 Million USD) as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore how much of Tianjin Lisheng Pharmaceutical Co Ltd's assets are long-term investments to see how much of total assets are deployed in long-term investments.
Tianjin Lisheng Pharmaceutical Co Ltd - Total Liabilities Trend (2006–2025)
This chart illustrates how Tianjin Lisheng Pharmaceutical Co Ltd's total liabilities have evolved over time, based on quarterly financial data. For the complete balance sheet picture, see 002393 current and non-current assets.
Tianjin Lisheng Pharmaceutical Co Ltd Competitors by Total Liabilities
The table below lists competitors of Tianjin Lisheng Pharmaceutical Co Ltd ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
First Tracks Biotherapeutics, Inc. Ordinary Shares When-Issued
NASDAQ:TRAXV
|
USA | $33.11 Million |
|
Shenzhen Sinovatio Technology Co Ltd Class A
SHE:002912
|
China | CN¥337.24 Million |
|
Cass Information Systems Inc
NASDAQ:CASS
|
USA | $2.29 Billion |
|
A&W Food Services of Canada
TO:AW
|
Canada | CA$1.01 Billion |
|
uPI Semiconductor Corp
TW:6719
|
Taiwan | NT$2.87 Billion |
|
Arena REIT
AU:ARF
|
Australia | AU$552.00 Million |
|
Shenzhen Kaizhong Precision Technology Co Ltd
SHE:002823
|
China | CN¥1.57 Billion |
|
Ningbo Marine Co Ltd
SHG:600798
|
China | CN¥1.88 Billion |
Liability Composition Analysis (2006–2025)
This chart breaks down Tianjin Lisheng Pharmaceutical Co Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. See debt-free asset ratio of Tianjin Lisheng Pharmaceutical Co Ltd to measure how much of total assets are equity-financed.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 4.52 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.19 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.16 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Tianjin Lisheng Pharmaceutical Co Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Tianjin Lisheng Pharmaceutical Co Ltd (2006–2025)
The table below shows the annual total liabilities of Tianjin Lisheng Pharmaceutical Co Ltd from 2006 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | CN¥890.89 Million ≈ $130.36 Million |
-9.60% |
| 2024-12-31 | CN¥985.54 Million ≈ $144.21 Million |
+12.35% |
| 2023-12-31 | CN¥877.17 Million ≈ $128.36 Million |
-6.85% |
| 2022-12-31 | CN¥941.66 Million ≈ $137.79 Million |
+20.66% |
| 2021-12-31 | CN¥780.42 Million ≈ $114.20 Million |
+8.38% |
| 2020-12-31 | CN¥720.09 Million ≈ $105.37 Million |
-15.86% |
| 2019-12-31 | CN¥855.85 Million ≈ $125.24 Million |
+21.42% |
| 2018-12-31 | CN¥704.85 Million ≈ $103.14 Million |
+17.02% |
| 2017-12-31 | CN¥602.32 Million ≈ $88.14 Million |
+27.99% |
| 2016-12-31 | CN¥470.60 Million ≈ $68.86 Million |
+7.07% |
| 2015-12-31 | CN¥439.50 Million ≈ $64.31 Million |
+30.07% |
| 2014-12-31 | CN¥337.89 Million ≈ $49.44 Million |
+13.31% |
| 2013-12-31 | CN¥298.20 Million ≈ $43.64 Million |
+101.31% |
| 2012-12-31 | CN¥148.13 Million ≈ $21.68 Million |
+131.22% |
| 2011-12-31 | CN¥64.07 Million ≈ $9.37 Million |
-16.93% |
| 2010-12-31 | CN¥77.12 Million ≈ $11.29 Million |
-81.25% |
| 2009-12-31 | CN¥411.26 Million ≈ $60.18 Million |
+51.99% |
| 2008-12-31 | CN¥270.58 Million ≈ $39.59 Million |
-38.77% |
| 2007-12-31 | CN¥441.87 Million ≈ $64.66 Million |
+6.47% |
| 2006-12-31 | CN¥415.03 Million ≈ $60.73 Million |
-- |
About Tianjin Lisheng Pharmaceutical Co Ltd
Tianjin Lisheng Pharmaceutical Co.,Ltd. engages in the research and development, production, and sale of pharmaceutical products in China and internationally. The company offers pharmaceutical, traditional Chinese medicine, and antibiotic products in various forms, such as oral solid dosage forms, soft capsules, sterile preparations, and raw materials primarily for cardiovascular and digestive sy… Read more